Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon Lowry

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Lancet (London, England)|April 15, 2008
Cardiotoxicity associated with sunitinibSubramanian Hariharan, Simon Lowry
Journal of the Royal Society of Medicine|July 4, 2006
CelecoxibRaymond Cheung, Simon Lowry
Clinical Therapeutics|March 18, 2008
Analgesic effectiveness of celecoxib and diclofenac in patients with osteoarthritis of the hip requiring joint replacement surgery: a 12-week, multicenter, randomized, double-blind, parallel-group, double-dummy, noninferiority studyPaul Emery, Tamas Koncz, Sharon Pan, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|December 17, 2013
Pharmacokinetics of recombinant human antithrombin in delivery and surgery patients with hereditary antithrombin deficiencyJoost DeJongh, Johan Frieling, Simon Lowry, et al.
Pharmacoeconomics - Open|March 29, 2020
The Budget Impact of Introducing Tildrakizumab to a United States Health Plan for Managing Moderate-to-Severe Plaque PsoriasisJustin Carrico, Yang Zhao, Xiaoying Jia, et al.
American Journal of Reproductive Immunology (New York, N.Y. : 1989)|March 1, 2013
Exploring the role of antithrombin replacement for the treatment of preeclampsia: a prospective randomized evaluation of the safety and efficacy of recombinant antithrombin in very preterm preeclampsia (PRESERVE-1)Michael J Paidas, Bahaeddine M Sibai, Elizabeth W Triche, et al.
Antimicrobial Agents and Chemotherapy|June 7, 2021
Efficacy of Antistaphylococcal Lysin LSVT-1701 in Combination with Daptomycin in Experimental Left-Sided Infective Endocarditis Due to Methicillin-Resistant Staphylococcus aureusDavid B Huang, Eric Gaukel, Nancy Kerzee, et al.
The Journal of Dermatological Treatment|April 3, 2020
Comparative cost-effectiveness of tildrakizumab and other commonly used treatments for moderate-to-severe psoriasisJashin J Wu, Xiaoying Jia, Yang Zhao, et al.
The Journal of Dermatological Treatment|July 4, 2019
Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasisBoni Elewski, Alan Menter, Jeffrey Crowley, et al.
The Journal of Dermatological Treatment|July 1, 2020
Cost-effectiveness of tildrakizumab for the treatment of moderate-to-severe psoriasis in the United StatesXiaoying Jia, Yang Zhao, Justin Carrico, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Lancet (London, England)|April 15, 2008
Cardiotoxicity associated with sunitinibSubramanian Hariharan, Simon Lowry
Journal of the Royal Society of Medicine|July 4, 2006
CelecoxibRaymond Cheung, Simon Lowry
Clinical Therapeutics|March 18, 2008
Analgesic effectiveness of celecoxib and diclofenac in patients with osteoarthritis of the hip requiring joint replacement surgery: a 12-week, multicenter, randomized, double-blind, parallel-group, double-dummy, noninferiority studyPaul Emery, Tamas Koncz, Sharon Pan, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|December 17, 2013
Pharmacokinetics of recombinant human antithrombin in delivery and surgery patients with hereditary antithrombin deficiencyJoost DeJongh, Johan Frieling, Simon Lowry, et al.
Pharmacoeconomics - Open|March 29, 2020
The Budget Impact of Introducing Tildrakizumab to a United States Health Plan for Managing Moderate-to-Severe Plaque PsoriasisJustin Carrico, Yang Zhao, Xiaoying Jia, et al.
American Journal of Reproductive Immunology (New York, N.Y. : 1989)|March 1, 2013
Exploring the role of antithrombin replacement for the treatment of preeclampsia: a prospective randomized evaluation of the safety and efficacy of recombinant antithrombin in very preterm preeclampsia (PRESERVE-1)Michael J Paidas, Bahaeddine M Sibai, Elizabeth W Triche, et al.
Antimicrobial Agents and Chemotherapy|June 7, 2021
Efficacy of Antistaphylococcal Lysin LSVT-1701 in Combination with Daptomycin in Experimental Left-Sided Infective Endocarditis Due to Methicillin-Resistant Staphylococcus aureusDavid B Huang, Eric Gaukel, Nancy Kerzee, et al.
The Journal of Dermatological Treatment|April 3, 2020
Comparative cost-effectiveness of tildrakizumab and other commonly used treatments for moderate-to-severe psoriasisJashin J Wu, Xiaoying Jia, Yang Zhao, et al.
The Journal of Dermatological Treatment|July 4, 2019
Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasisBoni Elewski, Alan Menter, Jeffrey Crowley, et al.
The Journal of Dermatological Treatment|July 1, 2020
Cost-effectiveness of tildrakizumab for the treatment of moderate-to-severe psoriasis in the United StatesXiaoying Jia, Yang Zhao, Justin Carrico, et al.
Pageof 2